News - Rare diseases, Sanofi

Filter

Current filters:

Rare diseasesSanofi

Popular Filters

1 to 25 of 26 results

Sanofi renews alliance with Regulus and ups investment by $10 million

Sanofi renews alliance with Regulus and ups investment by $10 million

05-02-2014

US pharma company Regulus Therapeutics has renewed its strategic alliance with French drug major Sanofi…

FinancialFranceOncologyPharmaceuticalRare diseasesRegulus TherapeuticsResearchSanofiUSA

Sanofi and MAbImprove LabEx collaborate on rare lung disease

Sanofi and MAbImprove LabEx collaborate on rare lung disease

24-01-2014

French drug major Sanofi and MAbImprove Laboratoire d'Excellence (LabEx), coordinated by France’s Universite…

PharmaceuticalRare diseasesResearchRespiratory and PulmonarySanofi

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Genzyme to invest $80 million to expand capacity for Fabrazyme

Genzyme to invest $80 million to expand capacity for Fabrazyme

15-10-2013

French drug major Sanofi’s US biotech subsidiary Genzyme says that it is investing $80 million to build…

BiotechnologyFabrazymeFinancialGenzymeNorth AmericaProductionRare diseasesSanofi

Sanofi and Aviesan renew their agreement to accelerate research in France

Sanofi and Aviesan renew their agreement to accelerate research in France

01-10-2013

Sanofi and Aviesan, the French National Alliance for Life Sciences and Health, have renewed for a period…

EuropePharmaceuticalRare diseasesResearchSanofi

Easier access to funded enzyme replacement therapy proposed in New Zealand

20-09-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC is providing greater funded access to the expensive…

Asia-PacificBiotechnologyFinancialGenzymeRare diseasesRelvar ElliptaSanofi

New Zealand reaches agreement with Sanofi to fund ALS drug

11-09-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announce the approval of an agreement with…

Asia-PacificNeurologicalPharmaceuticalRare diseasesRegulationRilutekSanofi

New Zealand to widen access for type 1 and type 3 Gaucher disease drug

07-08-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of a proposal to widen…

Asia-PacificBiotechnologyCerezymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Genzyme's eliglustat meets endpoints in Ph III studies for Gaucher disease

18-02-2013

US biotech firm Genzyme, a subsidiary if French drug major Sanofi (Euronext: SAN) has released positive…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder

30-01-2013

The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

News briefs on Sanofi, Novo Nordisk and GlaxoSmithKline/Amicus

20-12-2012

Two US subsidiaries of French drug major Sanofi (Euronext: SAN) have agreed to pay $109 million to resolve…

Amicus TherapeuticsAmigalDiabetesFIAspFinancialGlaxoSmithKlineHyalganIDegLiraLegalNorth AmericaNovo NordiskPharmaceuticalRare diseasesResearchSanofi

Makers of Kynamro and Fanaptum to appeal negative CHMP opinions

17-12-2012

French drug major Sanofi's (Euronext: SAN) subsidiary Genzyme and US partner Isis Pharmaceuticals (Nasdaq:…

BiotechnologyEuropeFanaptFanaptumGenzymeIsis PharmaceuticalsKynamroNeurologicalPharmaceuticalRare diseasesRegulationSanofiVanda Pharmaceuticals

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra

03-12-2012

Vertex Pharmaceuticals (Nasdaq: VRTX) says that Health Canada has approved Kalydeco (ivacaftor), the…

BiotechnologyKalydecoMenactraNorth AmericaPharmaceuticalRare diseasesRegulationSanofiSanofi PasteurVaccinesVertex

Alnylam gets upfront $22.5 million in RNAi link with Genzyme

23-10-2012

French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro

19-10-2012

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory yesterday voted by…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Genzyme and Isis file Kynamro NDA in USA

02-04-2012

Biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN), has submitted a New Drug…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Genzyme to start shipping Fabrazyme from newly-approved plant

01-03-2012

French drug major Sanofi's (Euronext: SAN) US subsidiary Genzyme says that it has begun shipping its…

BiotechnologyFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofi

Positive Ph II results for Genzyme’s oral Gaucher drug

09-02-2012

French drug major Sanofi’s (Euronext: SAN) US subsidiary Genzyme yesterday revealed four-year follow-up…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

Genzyme Framingham plant now cleared by US and EU regulators

24-01-2012

French drug major Sanofi (Euronext: SAN) said yesterday that the US Food and Drug Administration has…

BiotechnologyFabrazymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Ongoing supply problems for Genzyme’s Cerezyme

19-09-2011

US biotech Genzyme, now a subsidiary of French drug major Sanofi (Euronext: SAN), says it will have only…

BiotechnologyCerezymeFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofiShire

NIH scientists repurpose Genzyme’s FDA-approved plerixafor for rare disease

05-09-2011

A new study reports that a drug already approved by the US Food and Drug Administration for use in patients…

BiotechnologyGenzymeImmunologicalsMozobilPharmaceuticalPlerixaforRare diseasesResearchSanofi

PTC Therapeutics and Genzyme restructuring ataluren collaboration

04-09-2011

Privately-held PTC Therapeutics and fellow USA-based Genzyme, now part of French drug major Sanofi (Euronext:…

atalurenGenzymeLicensingPharmaceuticalPTC TherapeuticsRare diseasesSanofi

1 to 25 of 26 results

Back to top